Study Evaluating Single Doses of BLI-489 in Healthy Subjects

NCT00820404 ↗

Phase 1 Completed 54 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.

Timeline

Start: 2009-01
Primary completion: 2009-04
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BLI-489	Small molecule	—	Intravenous

Indications

No indication recorded.